Cargando…
Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitor as an Add-on Drug to GLP-1 Receptor Agonists for Glycemic Control of a Patient with Prader–Willi Syndrome: A Case Report
INTRODUCTION: Diabetes patients with Prader–Willi syndrome (PWS) are obese because of hyperphagia; weight control by dietary modification and medicine is required for glycemic control. There are several recent reports showing the effectiveness of GLP-1 receptor agonists (GLP-1RAs) for diabetes treat...
Autores principales: | Horikawa, Yukio, Enya, Mayumi, Komagata, Makie, Hashimoto, Ken-ichi, Kagami, Masayo, Fukami, Maki, Takeda, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801255/ https://www.ncbi.nlm.nih.gov/pubmed/29335890 http://dx.doi.org/10.1007/s13300-018-0369-5 |
Ejemplares similares
-
Genome-wide methylation analysis in Silver–Russell syndrome, Temple syndrome, and Prader–Willi syndrome
por: Hara-Isono, Kaori, et al.
Publicado: (2020) -
Three Siblings with Prader-Willi Syndrome: Brief Review of Sleep and Prader-Willi Syndrome
por: Bingeliene, Arina, et al.
Publicado: (2015) -
Genetics of Prader-Willi syndrome and Prader-Will-Like syndrome
por: Cheon, Chong Kun
Publicado: (2016) -
Efficacy of sodium-glucose cotransporter 2 inhibitor with glucagon-like
peptide-1 receptor agonist for the glycemic control of a patient with Prader-Willi
syndrome: a case report
por: Sano, Hitomi, et al.
Publicado: (2020) -
Epigenetics in Prader-Willi Syndrome
por: Mendiola, Aron Judd P., et al.
Publicado: (2021)